| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0140-6736(98)03391-1 |
| P8608 | Fatcat ID | release_cvq7l5mqyfbarol3oz7vnbhiuq |
| P698 | PubMed publication ID | 9652687 |
| P2093 | author name string | A Carr | |
| D J Chisholm | |||
| D A Cooper | |||
| K Samaras | |||
| P2860 | cites work | The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein | Q24339570 |
| Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 | Q27702268 | ||
| Crystal structure of cellular retinoic acid binding protein I shows increased access to the binding cavity due to formation of an intermolecular beta-sheet | Q27729587 | ||
| The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus | Q28190307 | ||
| Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist | Q28286186 | ||
| Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor | Q29547912 | ||
| 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma | Q29615221 | ||
| Retinoic acid biosynthesis and metabolism | Q34063235 | ||
| Hypertrophy of the breasts in a patient treated with indinavir | Q34444998 | ||
| Effects of nonesterified fatty acid availability on tissue-specific glucose utilization in rats in vivo | Q34557980 | ||
| Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. | Q37376673 | ||
| Structure/function of cytoplasmic vitamin A-binding proteins. | Q41138378 | ||
| Regulation of metabolism by retinoic acid and its nuclear receptors | Q41138384 | ||
| A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors | Q43613003 | ||
| Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists | Q46221014 | ||
| "Buffalo hump" in men with HIV-1 infection. | Q51571024 | ||
| Indinavir-associated lipodystrophy. | Q54138768 | ||
| The non-genetic determinants of central adiposity* | Q57258093 | ||
| Regulation of adipose cell number in man | Q73085437 | ||
| Visceral abdominal-fat accumulation associated with use of indinavir | Q74390712 | ||
| HIV-1 protease inhibitors | Q95819985 | ||
| P433 | issue | 9119 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV | Q15787 |
| insulin resistance | Q1053470 | ||
| hyperlipidemia | Q1079120 | ||
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 1881-1883 | |
| P577 | publication date | 1998-06-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance | |
| P478 | volume | 351 |
| Q44645516 | A Comparison of the Effects of Nevirapine and Nelfinavir on Metabolism and Body Habitus in Antiretroviral-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Controlled Study |
| Q44430928 | A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection |
| Q43886147 | A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia |
| Q33609283 | A risk-benefit assessment of HIV protease inhibitors |
| Q24563844 | A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides |
| Q59692422 | Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals |
| Q44940767 | Abnormalities in apolipoprotein and lipid levels in an HIV-infected Brazilian population under different treatment profiles: the relevance of apolipoprotein E genotypes and immunological status |
| Q37337474 | Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice |
| Q34722581 | Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series |
| Q34285949 | Adipocyte metabolism and the metabolic syndrome. |
| Q59326204 | Adipose tissue lipin expression levels distinguish HIV patients with and without lipodystrophy |
| Q34436519 | Advances in HIV treatment and treatment toxicities |
| Q34071132 | Adverse effects of antiretroviral therapy |
| Q24617882 | Adverse effects of antiretroviral therapy for HIV infection |
| Q34187120 | Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism |
| Q44969302 | Alterations in lipid profiles in HIV-infected patients treated with protease inhibitor therapy are not influenced by diet |
| Q33951340 | Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor |
| Q35569823 | An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature |
| Q35653299 | An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro |
| Q34216619 | Anti-retroviral therapy, insulin resistance and lipodystrophy |
| Q35547830 | Antipsychotics inhibit glucose transport: Determination of olanzapine binding site in Staphylococcus epidermidis glucose/H(+) symporter. |
| Q37304808 | Antiretroviral prescribing patterns in treatment-naïve patients in the United States. |
| Q36933854 | Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost? |
| Q45990511 | Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men. |
| Q38964625 | Antiretroviral treatment for HIV infection/AIDS and the risk of developing hyperglycemia and hyperlipidemia |
| Q43890540 | Antiretroviral treatment in 1998. |
| Q33188001 | Apoptosis of human abdominal preadipocytes before and after differentiation into adipocytes in culture. |
| Q37604387 | Apoptosis: a clinically useful measure of antiretroviral drug toxicity? |
| Q51440906 | Assessment of body fat composition disturbances by bioimpedance analysis in HIV-infected adults. |
| Q37302739 | Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients |
| Q27000959 | Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis |
| Q36498717 | Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study |
| Q40379251 | Associations Between At-Risk Alcohol Use, Substance Use, and Smoking with Lipohypertrophy and Lipoatrophy Among Patients Living with HIV. |
| Q37520935 | Associations between antiretroviral use and subclinical coronary atherosclerosis. |
| Q36070094 | Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population |
| Q77367342 | Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities |
| Q59138073 | Benchmarks of Diabetes Care in Men Living With Treated HIV-Infection: A Tertiary Center Experience |
| Q44242901 | Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance |
| Q46829672 | Bilateral lipomastia in men: a side effect of highly active antiretroviral therapy |
| Q38953001 | Biochemical Manifestation of HIV Lipodystrophy Syndrome |
| Q42273064 | Body composition in prepubertal, HIV-infected children: a comparison of bioelectrical impedance analysis and dual-energy X-ray absorptiometry |
| Q36206201 | Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors |
| Q47262823 | Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients. |
| Q37341305 | Body-fat abnormalities in patients with HIV: progress and challenges |
| Q50270064 | Breast Hypertrophy Induced by Ombitasvir/Paritaprevir/Ritonavir and Ribavirina. |
| Q53851252 | British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). |
| Q35009815 | Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir) |
| Q36011828 | Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. |
| Q38521176 | Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy |
| Q42197898 | Cerebrovascular events in HIV-infected patients: an analysis of a cohort of 3203 HIV+ patients during the times of cART. |
| Q36052990 | Changes in HIV and AIDS in the United States: Entering the Third Decade |
| Q64131888 | Changes in HIV and AIDS in the United States: entering the third decade |
| Q37705891 | Changes in Lipid Profiles and Other Biochemical Parameters in HIV-1 Infected Patients Newly Commenced on HAART Regimen |
| Q56450419 | Chronic use of indinavir in albino rat pregnancy (Rattus norvegicus albinus, Rodentia, Mammalia): Biological assay |
| Q44224684 | Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance. |
| Q38723259 | Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients |
| Q34023081 | Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity |
| Q56539634 | Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study |
| Q35833918 | Combination antiretroviral therapy and chronic HIV infection affect serum retinoid concentrations: longitudinal and cross-sectional assessments |
| Q43602324 | Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir |
| Q33825654 | Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection |
| Q34052597 | Coronary artery disease and human immunodeficiency virus infection |
| Q44435381 | Coronary artery disease in HIV infected patients |
| Q34397028 | Coronary heart disease associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors: report of four cases and review |
| Q36103159 | Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients |
| Q34660778 | Cytokine therapy or structured treatment interruptions in HIV infection: which is best? |
| Q37247615 | Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals |
| Q82385263 | DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued |
| Q35152206 | Deficiency of PXR decreases atherosclerosis in apoE-deficient mice |
| Q52164434 | Developmental toxicity of the HIV-protease inhibitor indinavir in rats. |
| Q38282023 | Diabetes and HIV. |
| Q33404972 | Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). |
| Q46765257 | Diabetes, metabolic syndrome and dyslipidemia in people living with HIV in Africa: re-emerging challenges not to be forgotten |
| Q44820677 | Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study |
| Q35000755 | Dimerization inhibitors of HIV-1 protease |
| Q38109095 | Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. |
| Q36920662 | Drug-induced cardiovascular disorders |
| Q37319195 | Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection |
| Q46602354 | Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 infected pregnant women |
| Q44770142 | Effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-naïve infected patients |
| Q47112253 | Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era. |
| Q39342992 | Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study |
| Q44318804 | Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells |
| Q90115605 | Effect of the duration of protease inhibitor therapy in HIV-infected individuals on the severity of obstructive sleep apnea |
| Q35053466 | Effects of HIV protease inhibitor therapy on lipid metabolism |
| Q34312147 | Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis |
| Q34141274 | Emerging concepts in gastrointestinal aspects of HIV-1 pathogenesis and management |
| Q36592761 | Endothelial dysfunction in HIV infection |
| Q38086841 | Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy |
| Q47100840 | Epigenetic impact of endocrine disrupting chemicals on lipid homeostasis and atherosclerosis: a pregnane X receptor-centric view |
| Q34335180 | Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors |
| Q34743413 | Evaluation and management of dyslipidemia in patients with HIV infection |
| Q24608464 | Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline |
| Q58764782 | Evaluation of Oral Antiretroviral Drugs in Mice With Metabolic and Neurologic Complications |
| Q35462419 | Evolutionary distance of amino acid sequence orthologs across macaque subspecies: identifying candidate genes for SIV resistance in Chinese rhesus macaques |
| Q57915299 | Exercise and Physical Activity and Long-Term Management of HIV |
| Q44453392 | Facial lipoatrophy: report of five cases after injection of synthetic filler into naso-labial folds |
| Q53691000 | Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update. |
| Q56529459 | Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study |
| Q35513728 | Fasting Triglyceride Concentrations are Associated with Early Mortality Following Antiretroviral Therapy in Zambia |
| Q35194387 | Fat distribution in men with HIV infection |
| Q35194384 | Fat distribution in women with HIV infection |
| Q43620342 | Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor |
| Q45722414 | Frequency of and outcome of acute coronary syndromes in patients with human immunodeficiency virus infection |
| Q34253209 | From lipodystrophy syndromes to diabetes mellitus |
| Q37828539 | From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir |
| Q35793960 | Gender-specific effects of HIV protease inhibitors on body mass in mice |
| Q80843267 | Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia |
| Q34191314 | Glucose disorders associated with HIV and its drug therapy |
| Q46957631 | Glucose-stimulated prehepatic insulin secretion is associated with circulating alanine, triglyceride, glucagon, lactate and TNF-alpha in patients with HIV-lipodystrophy |
| Q34699524 | Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective |
| Q43176625 | Gonadotrophic axis dysfunction in men with HIV-infection/aids |
| Q30239101 | HIV and its relationship to insulin resistance and lipid abnormalities. |
| Q34056448 | HIV disease in the year 2000. |
| Q33640993 | HIV disease treatment in the era of HAART. |
| Q38413754 | HIV infection : chronic disease with comorbidities |
| Q73048644 | HIV nucleoside analogues: new adverse effects on mitochondria? |
| Q43730373 | HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus |
| Q33946902 | HIV protease inhibitor-related lipodystrophy syndrome |
| Q44922052 | HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. |
| Q35060359 | HIV protease inhibitors and atherosclerosis |
| Q34792983 | HIV protease inhibitors and obesity |
| Q40747284 | HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma |
| Q74341382 | HIV protease inhibitors block adipogenesis and increase lipolysis in vitro |
| Q43811445 | HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia |
| Q35562568 | HIV protease inhibitors, the lipodystrophy syndrome and polycystic ovary syndrome--is there a link? |
| Q33604216 | HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications |
| Q37519715 | HIV protease inhibitors: recent clinical trials and recommendations on use. |
| Q33361587 | HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study |
| Q83351244 | HIV testing among Deep South residents 50 to 64 years old with cardiovascular disease and/or diabetes |
| Q36781531 | HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression |
| Q41369732 | HIV-1 infection and the PPARγ-dependent control of adipose tissue physiology |
| Q39881130 | HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone |
| Q33946920 | HIV-1 protease inhibitors |
| Q37018213 | HIV-associated dyslipidaemia: pathogenesis and treatment |
| Q34459421 | HIV-associated lipodystrophy |
| Q33821297 | HIV-associated lipodystrophy syndrome |
| Q41731830 | HIV-associated metabolic and morphologic abnormality syndrome. Welcome therapy may have unwelcome effects |
| Q35769323 | HIV-related lipodystrophy and related factors |
| Q34636927 | Haemophilia 2002: emerging risks of treatment |
| Q24814179 | High frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virus |
| Q37202281 | Hormonal contraception and HIV-positive women: metabolic concerns and management strategies |
| Q37045107 | Hospitalization due to adverse drug reactions and drug interactions before and after HAART. |
| Q50103684 | Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update. |
| Q33881280 | Human body composition: in vivo methods |
| Q35104006 | Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease |
| Q35875848 | Human immunodeficiency virus infection and the liver |
| Q45751680 | Human immunodeficiency virus protease inhibitors |
| Q54063351 | Human obesity and thinness, hyperlipidemia, hyperglycemia, and insulin resistance associated with HIV1 protease inhibitors. Prevention by alternating several antiproteases in short sequences. |
| Q33941936 | Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population |
| Q33926941 | Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment |
| Q35696547 | Hyperlipidemia in children with HIV infection: an emerging problem |
| Q77372902 | Hyperlipidemia under treatment with proteinase inhibitors |
| Q35176441 | Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution |
| Q24314564 | Identification and characterization of a novel retroviral-like aspartic protease specifically expressed in human epidermis |
| Q53653066 | Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection. |
| Q58065005 | Immunomodulators as adjunctive therapy for HIV-1 infection |
| Q34024617 | Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients |
| Q36763762 | Impact of age on markers of HIV-1 disease |
| Q54268216 | Impact of cocaine use on protease inhibitor-associated dyslipidemia in HIV-infected adults. |
| Q39382047 | In vivo assessment of antiretroviral therapy-associated side effects. |
| Q45863691 | Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders |
| Q42440254 | Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues |
| Q34984839 | Indinavir-induced retinoid-like effects: incidence, clinical features and management |
| Q33826230 | Indinavir: a review of its use in the management of HIV infection |
| Q34648909 | Influence of mitochondrial control of apoptosis on the pathogenesis, complications and treatment of HIV infection |
| Q53842118 | Influence of protease inhibitor therapy on lipoprotein metabolism. |
| Q40087155 | Insulin resistance and associated factors among HIV-infected patients in sub-Saharan Africa: a cross sectional study from Cameroon. |
| Q34983265 | Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. |
| Q35555694 | Intestinal pregnane X receptor links xenobiotic exposure and hypercholesterolemia |
| Q37650120 | Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action |
| Q46979848 | Is chromium an important element in HIV-positive patients with metabolic abnormalities? An hypothesis generating pilot study |
| Q51907859 | Is estimated cardiovascular risk higher in HIV-infected patients than in the general population? |
| Q44004417 | LDL-receptors expression in HIV-infected patients: relations to antiretroviral therapy, hormonal status, and presence of lipodystrophy |
| Q35614719 | Lack of an effect of protease inhibitor use on glucose tolerance during pregnancy |
| Q44776497 | Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors |
| Q35239494 | Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications |
| Q35210661 | Life without white fat: a transgenic mouse |
| Q44904599 | Lipid disorders in patients with HIV-induced diseases |
| Q34370958 | Lipid-induced insulin resistance: unravelling the mechanism |
| Q45396970 | Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus |
| Q43672221 | Lipodystrophies |
| Q44520144 | Lipodystrophy associated with protease inhibitors |
| Q34367498 | Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance |
| Q44551426 | Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors |
| Q44404100 | Lipodystrophy syndrome associated with the human immunodeficiency syndrome virus (I). General characteristics and etiopathogenesis |
| Q33983927 | Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? |
| Q43667547 | Lipodystrophy syndrome in children infected with human immunodeficiency virus |
| Q34248411 | Lipodystrophy syndrome in patients with HIV infection: quality of life issues |
| Q45739557 | Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine |
| Q40903070 | Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice |
| Q35513234 | Longitudinal analysis of bone density in human immunodeficiency virus-infected women |
| Q44198025 | Longitudinal evolution of HIV-1-associated lipodystrophy is correlated to serum cortisol:DHEA ratio and IFN-alpha |
| Q24242088 | Low dose versus high dose stavudine for treating people with HIV infection |
| Q44738362 | Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients |
| Q43818104 | Low plasma levels of dehydroepiandrosterone (DHEA) and incidence of lipodystrophy |
| Q58798902 | Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study |
| Q44594339 | Low serum carnitine in HIV-infected children on antiretroviral treatment |
| Q52722319 | Lower Concentrations of Circulating Medium and Long-Chain Acylcarnitines Characterize Insulin Resistance in Persons with HIV. |
| Q36699841 | Magnetic resonance imaging for quantifying regional adipose tissue in human immunodeficiency virus-infected persons with the cardiometabolic syndrome |
| Q35087365 | Management of the insulin resistance syndrome |
| Q36021411 | Management of the metabolic effects of HIV and HIV drugs |
| Q44763937 | Managing HIV lipoatrophy |
| Q33851998 | Medical management of HIV disease in children |
| Q33333867 | Medical significance of peroxisome proliferator-activated receptors. |
| Q39670294 | Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors |
| Q77298472 | Metabolic abnormalities and use of HIV-1 protease inhibitors |
| Q34942750 | Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional survey. |
| Q35592375 | Metabolic complications associated with HIV protease inhibitor therapy |
| Q34305866 | Metabolic complications associated with antiretroviral therapy |
| Q37385188 | Metabolic syndrome associated with HIV and highly active antiretroviral therapy |
| Q64039240 | Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers |
| Q36714593 | Minocycline- and tetracycline-induced hypertriglyceridemia in an HIV-seropositive patient receiving combination antiretroviral therapy |
| Q34464649 | Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders? |
| Q45285373 | Mitochondrial involvement in antiretroviral therapy-related lipodystrophy of HIV-infected patients |
| Q33745859 | Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy |
| Q37736324 | Modern trends in lipomodeling |
| Q44499492 | Modulation of the LDL receptor and LRP levels by HIV protease inhibitors |
| Q34207689 | Molecular basis of partial lipodystrophy and prospects for therapy |
| Q36211491 | Molecular mechanisms of HIV-1 associated neurodegeneration |
| Q35546584 | Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome |
| Q34050577 | Morphogenesis of the developing mammary gland: stage-dependent impact of adipocytes. |
| Q45739840 | Multiple circumscribed subcutaneous lipomas associated with use of human immunodeficiency virus protease inhibitors? |
| Q33592439 | Nelfinavir mesylate: a protease inhibitor |
| Q44724352 | Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection. |
| Q37271807 | New options in the treatment of lipid disorders in HIV-infected patients |
| Q33706638 | New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review. |
| Q30251861 | Novel functions of PXR in cardiometabolic disease |
| Q34906959 | Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides |
| Q34564488 | Nutrition and HIV infection |
| Q33798985 | Nutrition and immune function in human immunodeficiency virus infection. |
| Q38061798 | Nutrition and the HIV-associated lipodystrophy syndrome |
| Q33927664 | Nutrition in paediatric human immunodeficiency virus infection |
| Q39964157 | Nutritional and clinical status, and dietary patterns of people living with HIV/AIDS in ambulatory care in Sao Paulo, Brazil |
| Q42125460 | Paracardial lipodystrophy versus pericardial effusion in HIV positive patients |
| Q73953962 | Partial lipodystrophy, polycystic ovary syndrome and proteinuria: a common link to insulin resistance? |
| Q34547836 | Pathogenesis of HIV-associated cardiovascular complications |
| Q35193326 | Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s |
| Q28202926 | Peroxisome proliferator-activated receptors in cutaneous biology |
| Q34444007 | Perspective on HIV infection and aging: emerging research on the horizon |
| Q37727725 | Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo. |
| Q34633248 | Pharmacologic treatment of mood disorders in acquired immune deficiency syndrome (AIDS). |
| Q38172305 | Pharmacological management of cardiovascular conditions and diabetes in older adults with HIV infection |
| Q34674498 | Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for cardiovascular prevention'. |
| Q41731825 | Practical approaches to HIV therapy. Recommendations for the year 2000. |
| Q44618019 | Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report. |
| Q35195032 | Prevalence and factors associated with dry skin in HIV infection: the FRAM study |
| Q42225235 | Prevalence and factors associated with lipodystrophy in AIDS patients |
| Q54052663 | Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. |
| Q78222299 | Probing the role of interfacial residues in a dimerization inhibitor of HIV-1 protease |
| Q33854196 | Procedure, applications, and outcomes of autologous fat grafting |
| Q45096972 | Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study). |
| Q46246984 | Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection |
| Q44879927 | Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients. |
| Q44081426 | Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy |
| Q28344599 | Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype |
| Q34049924 | Protease inhibitor therapy and bleeding |
| Q54068035 | Protease inhibitor-associated angiolipomatosis. |
| Q38528072 | Protease inhibitor-induced lipodystrophy |
| Q42826034 | Protease inhibitors and adipocyte differentiation in cell culture. |
| Q41768073 | Protease inhibitors in HIV infection. Lipodystrophy may be a consequence of prolonged survival |
| Q46117356 | Rat chemokine CXCL11: structure, tissue distribution, function and expression in cardiac transplantation models |
| Q73980863 | Recent developments in the treatment of HIV disease |
| Q38162985 | Recent patents and emerging therapeutics for HIV infections: a focus on protease inhibitors |
| Q43695426 | Recurrent ingrown toenails secondary to indinavir/ritonavir combination therapy |
| Q40085569 | Relationship between estimated cardiovascular disease risk and insulin resistance in a black African population living with HIV: a cross-sectional study from Cameroon. |
| Q37192579 | Repositioning HIV protease inhibitors as cancer therapeutics |
| Q37016598 | Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. |
| Q44024381 | Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment |
| Q34091370 | Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study |
| Q59341936 | Ritonavir incrementa la expresión de CD36 y ABCA1 en macrófagos THP-1 |
| Q43866031 | Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients |
| Q37563409 | Role of pregnane X receptor in obesity and glucose homeostasis in male mice |
| Q42834586 | Role of protease inhibitors and acylation stimulating protein in the adipogenesis in 3T3-L1 cells |
| Q44693675 | Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers |
| Q39607149 | Severe dyslipidemia and immune activation in HIV patients with dysglycemia |
| Q42807041 | Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy |
| Q33854860 | Sleep disordered breathing, fatigue, and sleepiness in HIV-infected and -uninfected men |
| Q34460031 | Sterol regulatory element-binding proteins and reactive oxygen species: potential role in highly-active antiretroviral therapy (HAART)-associated lipodystrophy |
| Q28372555 | Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir |
| Q33786358 | Strategies of antiretroviral therapy in adults |
| Q34056488 | Systemic manifestations of HIV infection |
| Q38239575 | Targeting strategies for delivery of anti-HIV drugs |
| Q27318414 | The Bile Acid Sensor FXR Protects against Dyslipidemia and Aortic Plaques Development Induced by the HIV Protease Inhibitor Ritonavir in Mice |
| Q34092295 | The Changing Epidemic of HIV. |
| Q44138786 | The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. |
| Q59806829 | The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality |
| Q37429096 | The Relationship Between HIV Infection and Cardiovascular Disease |
| Q32183747 | The Role of Caveolin 1 in HIV Infection and Pathogenesis |
| Q35557264 | The effect of aging, nutrition, and exercise during HIV infection |
| Q40625838 | The effect of human immunodeficiency virus-1 protease inhibitors on the toxicity of a variety of cells |
| Q43652600 | The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients |
| Q37815335 | The effects of exercise training on metabolic and morphological outcomes for people living with HIV: a systematic review of randomised controlled trials |
| Q40678924 | The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling |
| Q43574806 | The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. |
| Q34418859 | The fat redistribution syndrome in patients infected with HIV: measurements of body shape abnormalities |
| Q34122352 | The management of the clinical complications of antiretroviral therapy |
| Q34696505 | The molecular basis of genetic lipodystrophies |
| Q33865548 | The non-enumerable described retrovirus integrase inhibitors are not a lure, as evidenced by ten years of clinical experience |
| Q33827318 | The ophthalmologist and the global impact of the AIDS epidemic LV Edward Jackson Memorial Lecture |
| Q43818106 | The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition |
| Q27021950 | The roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolism |
| Q45750384 | The science behind autologous fat grafting |
| Q37400616 | The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism |
| Q28292365 | The thrifty genotype in type 2 diabetes: an unfinished symphony moving to its finale? |
| Q40637184 | Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses |
| Q44380825 | Thyroxine-derivatives of lipopeptides: bifunctional dimerization inhibitors of human immunodeficiency virus-1 protease |
| Q36544924 | Toxic metabolic syndrome associated with HAART. |
| Q35194751 | Toxicity of antiretroviral therapy and implications for drug development |
| Q36222023 | Treatment of dyslipidaemia in HIV-infected persons |
| Q44817515 | Treatment of lipodystrophy in patients with human immunodeficiency virus infection |
| Q28168652 | Treatment of metabolic syndrome |
| Q33639909 | Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis |
| Q37661017 | Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study |
| Q40601129 | Two novel single nucleotide polymorphisms in the promoter of the cellular retinoic acid binding protein II gene (CRABP-II). |
| Q42170740 | Ultrasonographic measurement of intra-abdominal fat thickness in HIV-infected patients treated or not with antiretroviral drugs and its correlation to lipid and glycemic profiles |
| Q44361070 | Ultrasonography in lesions of the carotid vessels in HIV positive patients |
| Q28378450 | Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases |
| Q37362924 | Up-regulation of alveolar macrophage matrix metalloproteinases in HIV1(+) smokers with early emphysema |
| Q35215799 | Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth |
| Q57259689 | Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets |
| Q73425110 | Why have ten or so nontoxic, retrovirus integrase inhibitors not been made available for AIDS treatment? A ten-year experience [correction of experiment] must liberate them |
| Q77365435 | [Advances in the therapy of HIV infection and implications for clinical research] |
| Q81501645 | [Angiolipomas and antiretroviral therapy] |
| Q43654835 | [Antiretroviral therapy and cardiovascular risk] |
| Q83887838 | [Cutaneous drug reactions in HIV-infected patients in the HAART era] |
| Q81484014 | [HALS: HIV-Lipodystrophy associated syndrome] |
| Q75233906 | [Is there an increased risk for cardiovascular disease in HIV-infected patients on antiretroviral therapy?] |
| Q80426454 | [Liver and antiretrovirals: hepatotoxicity, steatosis and monitoring of patients with liver disease] |
Search more.